Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Safe drug prescribing

Bruce Lange
CMAJ June 25, 2002 166 (13) 1650-1651;
Bruce Lange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The excellent article on safe drug prescribing for patients with renal insufficiency addresses many questions that pharmacists are asked by physicians in daily practice.1

However, in Table 5 a statement on COX-2 selective NSAIDs would have been useful, as many physicians believe that these agents have less potential to adversely affect renal function than older nonselective agents. No evidence exists to support this belief. The new COX-2 selective agents are similar in net effects on renal prostaglandin function to the older nonselective NSAIDs.2,3

In addition, another nephrotoxic drug class to watch out for is radiocontrast “dyes.” Exposure to intravenous radiocontrast agents for diagnostic and interventional procedures is quite common. Aside from considering non-ionic, low-osmolality agents and hydration, reasonable evidence suggests that pre-treatment with oral N-acetylcysteine may further reduce the risk of renal damage.4 Given its low cost and minimal toxicity, N-acetylcysteine should be considered in patients with renal insufficiency before they are exposed to parenteral radiocontrast agents.

Bruce Lange Clinical Pharmacist, Nephrology Royal Columbian Hospital New Westminster, BC

References

  1. 1.↵
    Kappel J, Caliss, P. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ 2002;166(4):473-7.
    OpenUrlFREE Full Text
  2. 2.↵
    Brater DC. Effects of NSAIDs on renal function: focus on COX-2 selective inhibition. Am J Med 1999;107(6A):65S-71S.
    OpenUrl
  3. 3.↵
    Kaplan-Machlis B, Klostermeyer B. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 1999;33:979-88.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Tepel M, van der Giet M, Schwartzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 166, Issue 13
25 Jun 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safe drug prescribing
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safe drug prescribing
Bruce Lange
CMAJ Jun 2002, 166 (13) 1650-1651;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Safe drug prescribing
Bruce Lange
CMAJ Jun 2002, 166 (13) 1650-1651;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Study authors don’t consider waning SARS-CoV-2 immunity after vaccination in their model
  • The authors respond to criticisms of their model parameters
  • Error in key model input
Show more Letters

Similar Articles

Collections

  • Topics
    • Nephrology
    • Pharmacology & toxicology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire